Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026

Quest Diagnostics sets October 22, 2026, before market open for its Q3 2026 earnings release and investor conference call.

Rhea-AI Summary

Quest Diagnostics (DGX) will release its third quarter 2026 financial results on Thursday, October 22, 2026, before the market opens. A conference call to discuss the results will begin at 8:30 a.m. Eastern Time and will be accessible by phone and live webcast via the company’s investor relations website.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 financial results on Thursday, October 22, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.

The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call.

A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers; no passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on October 22, 2026, until midnight Eastern Time on November 5, 2026.

Anyone listening to the call is encouraged to read the company's periodic reports on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

About Quest Diagnostics 
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors, and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-to-release-third-quarter-financial-results-on-october-22-2026-302886725.html

SOURCE Quest Diagnostics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can investors join Quest Diagnostics’ Q3 2026 earnings conference call?

Participants may dial 888-455-0391 within the U.S. and Canada or 773-756-0467 internationally, using passcode 7895081. The company suggests dialing in about 10 minutes before the 8:30 a.m. Eastern Time start. A live webcast will also be available at www.QuestDiagnostics.com/investor.

Will a replay of the Q3 2026 earnings call be available?

A replay will be available at www.QuestDiagnostics.com/investor and by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers, with no passcode required. Telephone replays will be accessible from approximately 10:30 a.m. Eastern Time on October 22, 2026, until midnight Eastern Time on November 5, 2026.

What additional information does Quest Diagnostics recommend listeners review?

The company encourages anyone listening to the call to read its periodic reports filed with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.